Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)

被引：37
|
作者：
Curigliano, Giuseppe [1 ,2 ]
Hu, Xichun [3 ]
Dent, Rebecca Alexandra [4 ]
Yonemori, Kan [5 ]
Barrios Sr, Carlos H. [6 ]
O'Shaughnessy, Joyce [7 ]
Wildiers, Hans [8 ]
Zhang, Qingyuan [9 ]
Im, Seock-Ah [10 ]
Saura, Cristina [11 ]
Biganzoli, Laura [12 ]
Sohn, Joohyuk [13 ]
Levy, Christelle [14 ]
Jacot, William [15 ]
Begbie, Natasha [16 ]
Ke, Jun [17 ]
Patel, Gargi Surendra [18 ]
Bardia, Aditya
机构：
[1] Univ Milan, Milan, Italy
[2] IRCCS, European Inst Oncol, Milan, Italy
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[5] Natl Canc Ctr, Tokyo, Japan
[6] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil
[7] Baylor Univ, US Oncol Network, Texas Oncol, Med Ctr, Dallas, TX USA
[8] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium
[9] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[11] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[12] Santo Stefano Hosp, Azienda USL Toscana Ctr, Dept Oncol, Prato, Italy
[13] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[14] Ctr Francois Baclesse, Caen, France
[15] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Montpellier, France
[16] AstraZeneca, Clin Dev, Late Stage Dev, Oncol R&D, Cambridge, England
[17] AstraZeneca, Biometr Oncol, Late Stage Dev, Oncol R&D, Waltham, MA USA
[18] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.17_suppl.LBA1000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1000
引用
收藏
页码：LBA1000 / LBA1000
页数：1
相关论文
共 50 条
  • [1] Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptorepositive (HR plus ) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)
    Salgado, R. F.
    Bardia, A.
    Curigliano, G.
    Hu, X.
    Dent, R. A.
    Pierga, J-Y.
    Tsurutani, J.
    Wildiers, H.
    Ricciardi, G. R. R.
    Marchio, C.
    Penault-Llorca, F.
    Bor-Angelier, C.
    Andrzejuk-Cwik, A.
    Darilay, A.
    Matsuo, T.
    Shami, R.
    Jones, F.
    Viale, G.
    ANNALS OF ONCOLOGY, 2024, 35 : 1213 - 1214
  • [2] Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06
    Hu, X.
    Curigliano, G.
    Yonemori, K.
    Bardia, A.
    Barrios, C. H. E.
    Sohn, J.
    Levy, C.
    Jacot, W.
    Tsurutani, J.
    Mezei, K.
    de Climens, A. Roborel
    Wu, X.
    Begbie, N.
    Mbanya, Z.
    Dent, R. A.
    ANNALS OF ONCOLOGY, 2024, 35 : 1214 - 1215
  • [3] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04
    Modi, Shanu
    Niikura, Naoki
    Yamashita, Toshinari
    Jacot, William
    Sohn, Joohyuk
    Tokunaga, Eriko
    Vidal, Maria Jesus
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yeesoo
    Ueno, Naoto T.
    Prat, Aleix
    Suto, Fumitaka
    Kuwahara, Yusuke
    McEwen, Robert
    Feng, Wenqin
    Goto, Hiroki
    Orbegoso, Cecilia
    Cameron, David A.
    Tsurutani, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice of chemotherapy in patients with hormone receptor-positive (HR+), HER2 low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: A randomized, global phase 3 trial (DESTINY-Breast06)
    Bardia, Aditya
    Barrios, Carlos
    Dent, Rebecca
    Hu, Xichun
    O'Shaughnessy, Joyce
    Yonemori, Kan
    Darilay, Annie
    Boston, Sarice
    Liu, Yufan
    Patel, Gargi
    Curigliano, Giuseppe
    CANCER RESEARCH, 2021, 81 (04)
  • [5] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Wang, Xiaojia
    Xu, Binghe
    Gambhire, Dhiraj
    Yung, Lotus
    Meinhardt, Gerold
    Wang, Yibin
    Harbeck, Nadia
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [6] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
    Modi, S.
    Jacot, W.
    Iwata, H.
    Park, Y. H.
    Vidal Losada, M. J.
    Li, W.
    Tsurutani, J.
    Zaman, K.
    Ueno, N. T.
    Prat, A.
    Papazisis, K.
    Rugo, H. S.
    Harbeck, N.
    Im, S-A.
    De Laurentiis, M.
    Orbegoso, C. M. A.
    Yung, L.
    Cheng, F-C.
    Cheng, Y.
    Cameron, D. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S334 - S335
  • [7] Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Ueno, N. T.
    Jacot, W.
    Yamashita, T.
    Sohn, J.
    Tokunaga, E.
    Prat, A.
    Tsurutani, J.
    Park, Y. H.
    Rugo, H. S.
    Xu, B.
    Cardoso, F.
    Mitri, Z.
    Mahtani, R.
    Dunton, K.
    Wang, Y.
    Gambhire, D.
    Cottone, F.
    Harbeck, N.
    Cameron, D. A.
    Modi, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S633
  • [8] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Im, Seock-Ah
    Iwata, Hiroji
    Curigliano, Giuseppe
    Kim, Sung-Bae
    Chiu, Joanne Wing-Yan
    Pedrini, Jose Luiz
    Li, Wei
    Yonemori, Kan
    Bianchini, Giampaolo
    Loi, Sherene
    Borges, Giuliano Santos
    Wang, Xian
    Bachelot, Thomas
    Nakatani, Shunsuke
    Ashfaque, Shahid
    Liang, Zhengkang
    Egorov, Anton
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03
    Hurvitz, S. A.
    Modi, S.
    Li, W.
    Park, Y. H.
    Chung, W.
    Kim, S-B.
    Cortes, J.
    Yamashita, T.
    Pedrini, J.
    Im, S-A.
    Tseng, L-M.
    Harbeck, N.
    Krop, I.
    Curigliano, G.
    Mathias, E.
    Cathcart, J.
    Cagnazzo, A.
    Ashfaque, S.
    Egorov, A.
    Andre, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S335 - S336
  • [10] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
    Tsurutani, J.
    Jacot, W.
    Yamashita, T.
    Riaz, F.
    Yerushalmi, R.
    Im, S-A.
    Niikura, N.
    Halser-Strub, U.
    Cortes, J.
    Wennstig, A-K.
    Chae, Y.
    Wang, X.
    Li, W.
    Simon, H.
    Masci, G.
    Tamburini, E.
    Aguilar, C. Orbegoso
    Tecson, K.
    Yung, L.
    Modi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S342 - S343
12345